UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
Building 1, Suite 311 |
||
| (Address of Principal Executive Offices) | (Zip Code) |
| Registrant’s Telephone Number, Including Area Code: |
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 12, 2026, the stockholders of Valion Bio, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated 2021 Equity Incentive Plan (the “2021 Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 272,000 shares (the “Plan Amendment”). The Plan Amendment became effective upon stockholder approval. Except for the increase in the share reserve and related conforming changes, the Plan Amendment did not change any other term or provision of the 2021 Plan.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On November 12, 2026, the Company held a special meeting of stockholders in a virtual format (the “Special Meeting”). As of the close of business on October 15, 2026, the record date for the Special Meeting, there were 2,155,637 shares of the Company’s common stock issued and outstanding and entitled to vote. At the Special Meeting, 1,125,685 shares, or approximately 52.22% of the shares entitled to vote, were represented virtually or by proxy, constituting a quorum. Holders of the Company’s Series A, Series B and Series C Non-Voting Convertible Preferred Stock were not entitled to vote those shares on the matters presented at the Special Meeting.
The proposals are more fully described in the Company’s Definitive Proxy Statement on Schedule 14A dated October 16, 2026 (the “Proxy Statement”). The description of the 2021 Plan and the Plan Amendment under Proposal 2 in the Proxy Statement is incorporated by reference into Item 5.02 of this Current Report.
Based on the final tabulation provided by Broadridge, the voting results on the proposals presented at the Special Meeting were as follows:
Proposal No. 1: The Company’s stockholders approved the proposal to grant discretionary authority to the Company’s board of directors (the “Board”) to amend the Company’s amended and restated certificate of incorporation to effect a reverse stock split of all issued and outstanding shares of common stock at a ratio of not less than 1-for-2 and not greater than 1-for-12, with the ratio to be determined by the Board at any time within twelve months from the date of stockholder approval, without further stockholder approval or authorization.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 681,523 | 444,153 | 9 | 0 |
Proposal No. 2: The Company’s stockholders approved the Plan Amendment to increase the number of shares of common stock authorized for issuance under the 2021 Plan by 272,000 shares.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 466,174 | 131,057 | 27 | 528,427 |
Proposal No. 3: The Company’s stockholders approved the proposal to authorize the Board, in its discretion, to adjourn the Special Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals.
| Votes For | Votes Against | Abstentions | Broker Non-Votes |
| 686,478 | 438,311 | 896 | 0 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| VALION BIO, INC. | |||
| Date: | November 16, 2026 | By: | /s/ Dean Zikria |
| Name: Dean Zikria Title: Interim Chief Executive Officer |
| 3 |